Please provide your email address to receive an email when new articles are posted on . Higher end-of-treatment hepatitis B surface antigen level correlated with nucleos(t)ide clinical relapse among ...
Please provide your email address to receive an email when new articles are posted on . Among patients with low baseline HBsAg, 39% achieved HBsAg loss with tobevibart/elebsiran, which rose to 46% ...
Treatment with bepirovirsen led to sustained clearance of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA for 24 weeks after the end of treatment for adults with chronic HBV in the ...
WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive ...
Hepatitis B virus (HBV) infection remains an urgent global health concern, affecting hundreds of millions of people and significantly heightening the risk of severe liver complications, including ...
Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals – – Company expects to dose first patient in Part B of the Phase 2 MARCH trial by the ...
Arbutus Biopharma Corporation announced promising data from a late-breaker poster presentation at the EASL Congress 2025, revealing that its treatment combining imdusiran, a RNAi therapeutic, with VTP ...
GSK’s bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B: London, UK Friday, February 27, 2026, 09:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results